CALIXAR is a biotech company specialized in the identification and isolation of functional membrane therapeutic targets and antigens (GPCRs, Ion channels, Transporters, …). The company is currently investing in the extension of its pipeline of highly druggable membrane protein targets and native antigens. Within the next few years, CALIXAR will be able to offer to Pharma companies native and functional therapeutic targets validated and in a ready-to-discovery format.Vincent CORVEST, Senior Scientist & Business Manager is glad to be part of the 2022 AMR Conference to exchange on CALIXAR’s capabilities that will be a key point in the development of small molecules, antimicrobial treatments and so on.Meet Vincent during the 2-day event and give yourself the chance to achieve your discovery projects.About the AMR Conference:The #AMRconference is a platform for SMEs, start-ups, big pharma, academia, investors, and public institutions to discuss strategies and the specific challenges faced by SMEs in bringing new antimicrobial treatments and diagnostics to the market.The “AMR Conference” was started in 2017 to offer a platform for meeting experts from business, science, clinics, finance, regulatory affairs, and intellectual property.For more information and meet us: AMR Conference
